Cipla Limited has announced a 60:40 joint venture with Kemwell Biopharma to develop, manufacture, and commercialize biologic products for global markets. Both partners will invest up to INR 10 crores in their respective JV ratio, marking a significant step in Cipla’s biologics expansion strategy.
Cipla has officially notified stock exchanges that the joint venture company will be incorporated in India, with Cipla subscribing to 6,000 shares at par value during incorporation. Kemwell, a leading Asia-based biologics CDMO, brings advanced capabilities including a US FDA-certified Bangalore cGMP site with 5,000 L bioreactor capacity, sterile fill-finish, and protein therapeutics development labs.
Key Highlights
-
Cipla and Kemwell Biopharma form a 60:40 joint venture in India
-
Focus on developing, licensing, manufacturing, and commercializing biologics globally
-
Initial investment up to INR 10 crores by partners in JV ratio
-
Kemwell’s US FDA-certified Bangalore facility offers advanced biologics manufacturing capabilities
-
JV aims to strengthen Cipla’s biologics pipeline and global market presence
This collaboration positions Cipla to expand its footprint in the fast-growing biologics segment, leveraging Kemwell’s expertise in contract development and manufacturing to accelerate innovation and commercialization.
Source: Cipla Limited, SEBI Intimation dated 2nd March 2026